Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second line therapy extended the length of time patients lived before their disease worsened (progression-free survival) compared with patients who received pomalidomide and dexamethasone.